Robotics
16 October 2026
Cytoreductive Nephrectomy for Metastatic Kidney Cancer: Who Still Benefits?
The therapeutic landscape for metastatic renal cell carcinoma (mRCC) has experienced a major paradigm shift over the past two decades. Historically, when cytokine-based immunotherapies (interferon-alpha and interleukin-2) represented the standard of care, upfront cytoreductive nephrectomy (CN)—the surgical removal of the primary kidney tumor in the setting of known distant metastatic spread—was mandatory. Randomized trials from […]